Delete search term


Quick navigation

Main navigation

Inpatient hospital costs of febrile neutropenia as a consequence of chemotherapy for breast cancer and Non-Hodgkin lymphoma in Switzerland

At a glance

  • Project leader : Renato Mattli, Mark Pletscher
  • Project team : Prof. Dr. Klaus Eichler, Prof. Dr. Simon Wieser
  • Project status : completed
  • Funding partner : Third party
  • Project partner : Amgen Switzerland AG
  • Contact person : Renato Mattli


Febrile neutropenia (FN) can be a serious complication of chemotherapy (CHT), increasing mortality risk and healthcare costs. Incidence and inpatient hospital costs of FN in Switzerland are currently not reported. The study aims to: 1. Estimate the number of CHT induced FN-related hospitalizations. 2. Assess inpatient hospital costs per FN event in Switzerland.